# Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer

> **NCT00077363** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 70 (actual)

## Conditions studied

- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** tipifarnib
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00077363
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2007-02
- **Final completion:** —
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2013-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077363, "Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00077363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*